CAD gene and early infantile epileptic encephalopathy-50; three Iranian deceased patients and a novel mutation: case report.


Journal

BMC pediatrics
ISSN: 1471-2431
Titre abrégé: BMC Pediatr
Pays: England
ID NLM: 100967804

Informations de publication

Date de publication:
11 03 2022
Historique:
received: 14 11 2021
accepted: 07 03 2022
entrez: 12 3 2022
pubmed: 13 3 2022
medline: 14 4 2022
Statut: epublish

Résumé

Early infantile epileptic encephalopathy is a severe form of epilepsy that is genetically extremely heterogeneous and characterized by seizures or spasms at the beginning of infancy. Homozygous or compound heterozygous mutation in the CAD gene cause early infantile epileptic encephalopathy-50 (EIEE50). This case report describes the clinical and molecular features of three patients affected with early infantile epileptic encephalopathy. In this report, we describe the clinical features of two deceased daughters and one recently deceased son affected with seizure, muscular hypotonia, and developmental delay. After genetic counseling, blood samples were obtained from the parents, and whole-exome sequencing was performed. Genomic DNA was extracted from whole blood, and mutation analysis was performed using PCR and sequencing methods for the CAD gene. Genetic analysis using the whole-exome sequencing method has detected a novel likely pathogenic mutation on CAD gene, c.2995G > A (p.Val999Met), in heterozygous states in asymptomatic parents and homozygous state in affected newborn son. This mutation has not been reported in the literature for its pathogenicity. The asymptomatic parents are carriers for the likely pathogenic variant in the CAD gene, and the recently deceased newborn son had the same mutation in a homozygous state. Given that, multiple lines of in silico computational analysis support the detrimental impact of the variant on the gene, and this variant is absent in population databases. Pathogenic mutations in the CAD gene are related to autosomal recessive EIEE50 with similar signs and symptoms to our patients. Ultimately, it is confirmed that this mutation is causative in our patients.

Sections du résumé

BACKGROUND
Early infantile epileptic encephalopathy is a severe form of epilepsy that is genetically extremely heterogeneous and characterized by seizures or spasms at the beginning of infancy. Homozygous or compound heterozygous mutation in the CAD gene cause early infantile epileptic encephalopathy-50 (EIEE50). This case report describes the clinical and molecular features of three patients affected with early infantile epileptic encephalopathy.
CASE PRESENTATION
In this report, we describe the clinical features of two deceased daughters and one recently deceased son affected with seizure, muscular hypotonia, and developmental delay. After genetic counseling, blood samples were obtained from the parents, and whole-exome sequencing was performed. Genomic DNA was extracted from whole blood, and mutation analysis was performed using PCR and sequencing methods for the CAD gene. Genetic analysis using the whole-exome sequencing method has detected a novel likely pathogenic mutation on CAD gene, c.2995G > A (p.Val999Met), in heterozygous states in asymptomatic parents and homozygous state in affected newborn son. This mutation has not been reported in the literature for its pathogenicity.
CONCLUSIONS
The asymptomatic parents are carriers for the likely pathogenic variant in the CAD gene, and the recently deceased newborn son had the same mutation in a homozygous state. Given that, multiple lines of in silico computational analysis support the detrimental impact of the variant on the gene, and this variant is absent in population databases. Pathogenic mutations in the CAD gene are related to autosomal recessive EIEE50 with similar signs and symptoms to our patients. Ultimately, it is confirmed that this mutation is causative in our patients.

Identifiants

pubmed: 35277149
doi: 10.1186/s12887-022-03195-4
pii: 10.1186/s12887-022-03195-4
pmc: PMC8915536
doi:

Substances chimiques

CAD trifunctional enzyme 0
Aspartate Carbamoyltransferase EC 2.1.3.2
Dihydroorotase EC 3.5.2.3
Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing) EC 6.3.5.5

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

125

Informations de copyright

© 2022. The Author(s).

Références

Brain. 2017 Feb;140(2):279-286
pubmed: 28007989
Glycoconj J. 1999 Feb;16(2):147-59
pubmed: 10612414
J Inherit Metab Dis. 2014 Sep;37(5):687-98
pubmed: 25030255
Hum Mol Genet. 2015 Jun 1;24(11):3050-7
pubmed: 25678555
Nat Genet. 2010 Jan;42(1):30-5
pubmed: 19915526
Am J Hematol. 2018 May;93(5):672-682
pubmed: 29396846
Am J Hum Genet. 2014 Feb 6;94(2):161-75
pubmed: 24507773
Hereditas. 1970;66(2):205-14
pubmed: 5004701
Cell Mol Life Sci. 2003 Feb;60(2):321-36
pubmed: 12678497
Nature. 2000 Jan 20;403(6767):328-32
pubmed: 10659854

Auteurs

Sepideh Gholami Yarahmadi (SG)

School of Advanced Sciences and Technology, Islamic Azad University-Tehran Medical Sciences, Tehran, Iran.

Saeid Morovvati (S)

School of Advanced Sciences and Technology, Islamic Azad University-Tehran Medical Sciences, Tehran, Iran. morovvati@iautmu.ac.ir.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH